• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[New therapeutic agents in the management of multiple sclerosis].

作者信息

Besson G, Carpentier F

出版信息

Presse Med. 1998 Dec 12;27(39):2032-5.

PMID:9893694
Abstract

UNLABELLED

THERAPEUTIC ADVANCES: Several effective therapies for multiple sclerosis capable of modifying the disease course in certain patients are now available in France.

INTERFERONS

Interferon beta-1b and interferon beta-1a have been given specific marketing approval in France for ambulatory patients with active relapsing-remitting multiple sclerosis. Interferon beta-1b has been shown to have a beneficial effect in progressive multiple sclerosis.

COPAXONE

This drug has a temporary authorization in France for ambulatory patients with relapsing-remitting multiple sclerosis who cannot tolerate interferon.

PERSPECTIVES

Other promising therapeutic options (mitoxantrone, intravenous immunoglobulins, drug associations) are under evaluation.

摘要

相似文献

1
[New therapeutic agents in the management of multiple sclerosis].
Presse Med. 1998 Dec 12;27(39):2032-5.
2
What is new in the treatment of multiple sclerosis?多发性硬化症治疗方面有哪些新进展？
Drugs. 2000 Mar;59(3):401-10. doi: 10.2165/00003495-200059030-00002.
3
Contemporary immunomodulatory therapy for multiple sclerosis.多发性硬化症的当代免疫调节疗法。
J Neuroophthalmol. 2001 Dec;21(4):284-91. doi: 10.1097/00041327-200112000-00012.
4
Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics.
Arch Neurol. 1999 Sep;56(9):1079-84. doi: 10.1001/archneur.56.9.1079.
5
A prospective, open-label treatment trial to compare the effect of IFN beta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis.一项前瞻性、开放标签治疗试验，比较干扰素β-1a（阿沃尼单抗）、干扰素β-1b（倍泰龙）和醋酸格拉替雷（考帕松）对复发缓解型多发性硬化症复发率的影响。
Eur J Neurol. 2001 Mar;8(2):141-8. doi: 10.1046/j.1468-1331.2001.00189.x.
6
Combination therapies in multiple sclerosis.多发性硬化症的联合疗法。
J Neurol. 2008 Mar;255 Suppl 1:51-60. doi: 10.1007/s00415-008-1008-2.
7
Current disease-modifying therapies in multiple sclerosis.目前用于治疗多发性硬化症的疾病修正疗法。
Semin Neurol. 2003 Jun;23(2):133-46. doi: 10.1055/s-2003-41138.
8
[Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].β-干扰素和考帕松++在多发性硬化症治疗中的应用问题与前景
Zh Nevrol Psikhiatr Im S S Korsakova. 1999;99(4):33-6.
9
Multiple sclerosis treatment 2001.2001年多发性硬化症治疗
Neurol Clin. 2001 Feb;19(1):107-18. doi: 10.1016/s0733-8619(05)70007-4.
10
A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing--remitting multiple sclerosis: results after 18 months of therapy.一项前瞻性、开放标签治疗试验，比较干扰素β-1a（阿沃尼）、干扰素β-1b（倍泰龙）和醋酸格拉替雷（考帕松）对复发缓解型多发性硬化症复发率的影响：治疗18个月后的结果。
Mult Scler. 2001 Dec;7(6):349-53. doi: 10.1177/135245850100700601.